Technology

Introducing PDX Pharma’s Technology

PLATFORM (Pdx-NP™)

Our proprietary Pdx-NPTM is innovative silica-based drug delivery technology that can load multiple cargo types at once (e.g., oligonucleotides, adjuvants, antibodies, chemotherapeutics, proteins) with superior outcomes than the free drug counterparts, creating a myriad of new intellectual properties.** It can target both cancer and immune cells, generating cancer specific immune response.

* * To date, we have 33 patent applications pending examination and 3 US patents issued in Q3, 2021 – Q1, 2022, encompassing compositions and methods of use for our nanoparticle platform and novel combination therapeutics

IN SITU CANCER VACCINE STRATEGY WITH AIRISE™ AND ARAC™

Our first two candidates, AIRISE-02 and ARAC-02, utilize patients’ own tumors to create cancer specific immune response (CD8+ T cells). They bypass the need to identify tumor antigens or engineer T cells outside the body (e.g., CAR T cells). They can kill cancer cells and generate a tumor specific T cell response while modulating the immunosuppressive tumor environment.

Guo et al Front. Immunol 2018

Targeting Innate & Adaptive Immune Responses with AIRISE-02 And ARAC-02

AIRISE-02 has been published in Advanced Materials and won $2.0M award from the National Cancer Institute (NCI) in 2021.

ARAC-02 has been pre-printed in Nature Communications, achieved the perfect score during SBIR grant review, and won $2.3M award from the NCI in 2021.

KEY COMPETITIVE ADVANTAGES OF OUR NANO IMMUNO-THERAPEUTICS